Artia Global Partners LP Has $54.41 Million Position in argenex SE $ARGX

Artia Global Partners LP cut its holdings in argenex SE (NASDAQ:ARGX) by 17.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 64,699 shares of the company’s stock after selling 13,612 shares during the period. argenex makes up 7.5% of Artia Global Partners LP’s investment portfolio, making the stock its 2nd biggest holding. Artia Global Partners LP owned 0.10% of argenex worth $54,409,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Abound Wealth Management boosted its holdings in argenex by 3,200.0% in the fourth quarter. Abound Wealth Management now owns 33 shares of the company’s stock worth $28,000 after purchasing an additional 32 shares in the last quarter. Sound Income Strategies LLC bought a new stake in argenex in the fourth quarter worth $28,000. Ameriflex Group Inc. bought a new stake in argenex in the third quarter worth $32,000. Aventura Private Wealth LLC bought a new stake in argenex in the fourth quarter worth $38,000. Finally, Sunbelt Securities Inc. bought a new stake in argenex in the third quarter worth $36,000. 60.32% of the stock is currently owned by institutional investors.

argenex Stock Performance

NASDAQ ARGX opened at $892.26 on Thursday. The firm has a 50-day simple moving average of $820.36 and a 200 day simple moving average of $810.81. argenex SE has a twelve month low of $510.05 and a twelve month high of $934.62. The stock has a market cap of $55.49 billion, a PE ratio of 39.73, a PEG ratio of 1.34 and a beta of 0.47.

argenex (NASDAQ:ARGX) last released its earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. argenex had a net margin of 31.31% and a return on equity of 44.37%. The business had revenue of $1.31 billion during the quarter. Research analysts forecast that argenex SE will post 26.19 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on ARGX shares. Citizens Jmp upped their price target on shares of argenex from $925.00 to $944.00 and gave the company a “market outperform” rating in a report on Friday, February 27th. Deutsche Bank Aktiengesellschaft raised argenex from a “hold” rating to a “buy” rating in a research report on Tuesday, March 10th. Oppenheimer cut their price objective on argenex from $1,060.00 to $1,014.00 and set an “outperform” rating for the company in a research report on Thursday, April 2nd. Wall Street Zen cut argenex from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Finally, Wells Fargo & Company boosted their price objective on argenex from $1,260.00 to $1,291.00 and gave the stock an “overweight” rating in a research report on Monday, June 1st. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $1,019.50.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.